Chemomab Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. Their lead drug candidate, CM-101, targets CCL17 and CCL22 chemokines, which play a significant role in the pathogenesis of various fibrotic and inflammatory conditions. The company aims to address unmet medical needs in diseases such as idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and systemic sclerosis.